Mrk stock forecast the MRK stock forecast holds positive

The MRK stock forecast holds positive bias as hedge funds increase positions, evident from 13F filings showing a net uptick in holdings over the last reporting period. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The average prediction of analysts places 'Sales- Oncology- Keytruda' at $7.90 billion. The estimate indicates a year-over-year change of +8.7%. Options markets reflect heavy call positioning in the near term.